Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Haematologica|December 7, 2007
Atypical BCR-ABL mRNA transcripts in adult acute lymphoblastic leukemiaThomas Burmeister, Stefan Schwartz, Almut Taubald, et al.
Cancers|August 28, 2025
Prognostic Impact of the AML60+ Score for Elderly Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents: A Retrospective Multicentric AnalysisVerena Petermichl, Stefan Fuchs, Matthias Weber, et al.
Blood|February 26, 2025
Ibrutinib lead-in followed by venetoclax plus ibrutinib for relapsed/refractory chronic lymphocytic leukemia: the SAKK 34/17 trialAdalgisa Condoluci, Ilaria Romano, Daniel Dietrich, et al.
Acta Neuropathologica Communications|June 15, 2022
Visual imaging as a predictor of neurodegeneration in experimental autoimmune demyelination and multiple sclerosisGabrielle M Mey, Kirsten S Evonuk, McKenzie K Chappell, et al.
Haematologica|December 15, 2015
Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08)Christoph Driessen, Marianne Kraus, Markus Joerger, et al.
Cancer Investigation|September 20, 2006
Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphomaUlrich J M Mey, Katjana S Orlopp, Dimitri Flieger, et al.
British Journal of Haematology|December 17, 2016
Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2<sup>nd</sup> -line therapy for relapsed and refractory multiple myeloma - a phase II trialUlrich J M Mey, Wolfram Brugger, Heike Schwarb, et al.
Blood Advances|January 30, 2025
Six-month rituximab-lenalidomide regimen in advanced untreated follicular lymphoma: SAKK 35/10 trial 10-year updateEva Kimby, Sämi Schär, Maria Cristina Pirosa, et al.
Blood|May 19, 2019
Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapyEmanuele Zucca, Stephanie Rondeau, Anna Vanazzi, et al.
Pageof 3